Comment: The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated disease

Annals of Pharmacotherapy

Volumn 44, Issue 11, 2010, Pages 1855-1856

  Stevens, Vanessa ^a   Brown, Jack E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CLOSTRIDIUM DIFFICILE INFECTION; DISEASE ASSOCIATION; DRUG USE; INFECTION RISK; LETTER; PRIORITY JOURNAL; RISK FACTOR;

CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; FLUOROQUINOLONES; HUMANS; RESEARCH DESIGN; RISK FACTORS; TIME FACTORS;

EID: 78049465027     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M696a     Document Type: Letter

References (13)

1. Novell MJ, Morreale CA. The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated diarrhea. Ann Pharmacother 2010;44:826-31. DOI 10.1345/aph.1M696
2. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60. DOI 10.1086/496986
3. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45:1543-9. DOI 10.1086/523582
4. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29(1):44-50. DOI 10.1086/524320
5. Delaney JA, Dial S, Barkun A, Suissa S. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007;13:761-3.
6. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640-5. DOI 10.1086/381551
7. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730-3.
8. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80. DOI 10.1086/502539
9. Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001;22:572-5. DOI 10.1086/501954
10. Dhalla IA, Mamdani MM, Simor AE, Kopp A, Rochon PA, Juurlink DN. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antimicrob Agents Chemother 2006; 50:3216-9. DOI 10.1128/aac.00592-06
11. Woodward M. Epidemiology: study design and data analysis. 2nd ed. New York: Chapman & Hall/CRC, 2005.
12. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40. DOI 10.1056/NEJMra0707500
13. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-36. DOI 10.1038/nrmicro2164